Obstetrical Antiphospholipid Syndrome

ABSTRACT

Antiphospholipid syndrome (APS) is an autoimmune disease manifested by a thrombotic or obstetrical event in the presence of antiphospholipid antibodies. Obstetrical APS was initially described in the 1950s. Obstetrical features presently include recurrent pre-embryonic and embryonic miscarriage, fetal demise, preeclampsia, intrauterine growth restriction, and possibly placental abruption. Since the first description of obstetrical APS, researchers have unraveled some of the pathophysiology involved in the disease. At present, there are numerous antiphospholipid antibodies that can be measured in human serum, each of which requires evaluation with regard to whether an association with obstetrical events exists. Clinical trials have provided some insight into optimal treatment protocols, but to date, such trials are limited. On the basis of small, randomized trials, live birth rates of approximately 70 to 80% have been reported with the use of low-dose acetylsalicylic acid and heparin. Despite such encouraging results, ongoing pregnancies are fraught with maternal and fetal morbidity. This review will highlight the obstetrical morbidity associated with APS, discuss the limitations of the present criteria for diagnosis, appraise published treatment trials, and summarize directions for future study of obstetrical APS.

Antiphospholipid syndrome - antiphospholipid antibodies - recurrent miscarriage - fetal demise - heparin

REFERENCES

• 1 Wilson W A, Gharavi A E, Koike T et al.. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop.  Arthritis Rheum. 1999;  42 1309-1311
• 2 Branch D W, Silver R M, Blackwell J L, Reading J C, Scott J R. Outcome of treated pregnancies in women with antiphospholipid syndrome: an update of the Utah experience.  Obstet Gynecol. 1992;  80 614-620
• 3 Lima F, Khamashta M A, Buchanan N M, Kerslake S, Hunt B J, Hughes G R. A study of sixty pregnancies in patients with the antiphospholipid syndrome.  Clin Exp Rheumatol. 1996;  14 131-136
• 4 Backos M, Rai R, Baxter N, Chilcott I T, Cohen H, Regan L. Pregnancy complications in women with recurrent miscarriage associated with antiphospholipid antibodies treated with low dose aspirin and heparin.  Br J Obstet Gynaecol. 1999;  106 102-107
• 5 Kutteh W H, Rote N S, Silver R. Antiphospholipid antibodies and reproduction: the antiphospholipid antibody syndrome.  Am J Reprod Immunol. 1999;  41 133-152
• 6 Lockshin M D. Antiphospholipid antibody. Babies, blood clots, biology.  JAMA. 1997;  277 1549-1551
• 7 Stephenson M D. Frequency of factors associated with habitual abortion in 197 couples.  Fertil Steril. 1996;  66 24-29
• 8 Rai R S, Clifford K, Cohen H, Regan L. High prospective fetal loss rate in untreated pregnancies of women with recurrent miscarriage and antiphospholipid antibodies.  Hum Reprod. 1995;  10 3301-3304
• 9 Branch D W, Silver R, Pierangeli S, van Leeuwen I, Harris E N. Antiphospholipid antibodies other than lupus anticoagulant and anticardiolipin antibodies in women with recurrent pregnancy loss, fertile controls, and antiphospholipid syndrome.  Obstet Gynecol. 1997;  89 549-555
• 10 Hughes G R. The antiphospholipid syndrome: ten years on.  Lancet. 1993;  342 341-344
• 11 Hughes G R. Hughes syndrome-the syndrome behind the name (otherwise known as antiphospholipid syndrome).  Isr Med Assoc J. 1999;  1 100-103
• 12 Kutteh W H. Antiphospholipid antibodies and reproduction.  J Reprod Immunol. 1997;  35 151-171
• 13 Geva E, Amit A, Lerner-Geva L, Lessing J B. Autoimmunity and reproduction.  Fertil Steril. 1997;  67 599-611
• 14 Hatasaka H H, Branch D W, Kutteh W H, Scott J R. Autoantibody screening for infertility: explaining the unexplained?.  J Reprod Immunol. 1997;  34 137-153
• 15 Van Voorhis B J, Stovall D W. Autoantibodies and infertility: a review of the literature.  J Reprod Immunol. 1997;  33 239-256
• 16 Hornstein M D, Davis O K, Massey J B, Paulson R J, Collins J A. Antiphospholipid antibodies and in vitro fertilization success: a meta-analysis.  Fertil Steril. 2000;  73 330-333
• 17 Wasserman A, Neisser A, Bruck C. Eine serodiagnostiche Reaktion bei Syphilis.  Dtsch Med Wochenschr. 1906;  32 745-746
• 18 Pangborn M C. A new serologically active phospholipid from beef heart.  Proc Soc Exp Biol Med. 1941;  48 484-486
• 19 Moore J E, Mohr C F. Biologically false positive serologic tests for syphilis.  JAMA. 1952;  150 467-473
• 20 Conley C L, Hartman R C. A hemorrhagic disorder caused by circulating anticoagulant in patients with disseminated lupus erythematosus.  J Clin Invest. 1952;  31 621
• 21 Bell W N, Alton H. A brain extract as a substitute for platelet suspensions in the thromboplastin generation test.  Nature. 1954;  174 880-881
• 22 Bowie E, Thompson Jr J, Pascuzzi C A, Owen Jr C. Thrombosis in systemic lupus erythematosus despite circulating anticoagulants.  J Lab Clin Med. 1963;  62 416-430
• 23 Laurell A, Nilsson I M. Hypergammaglobulinemia, circulating anticoagulant, and biologic false positive Wassermann reaction; a study in two cases.  J Lab Clin Med. 1957;  49 694-707
• 24 Beaumont J L. Acquired hemorrhagic syndrome caused by a circulating anticoagulant; inhibition of the thromboplastic function of the blood platelets; description of a specific test.  Sang. 1954;  25 1-15
• 25 Nilsson I M, Astedt B, Hedner U, Berezin D. Intrauterine death and circulating anticoagulant (“antithromboplastin”).  Acta Med Scand. 1975;  197 153-159
• 26 Carreras L O, Defreyn G, Machin S J et al.. Arterial thrombosis, intrauterine death and “lupus” anticoagulant: detection of immunoglobulin interfering with prostacyclin formation.  Lancet. 1981;  1 241-246
• 27 Hughes G R. The anticardiolipin syndrome.  Clin Exp Rheumatol. 1985;  3 285-286
• 28 Harris E N, Gharavi A E, Boey M L et al.. Anticardiolipin antibodies: detection by radioimmunoassay and association with thrombosis in systemic lupus erythematosus.  Lancet. 1983;  2 1211-1214
• 29 Hughes G R. Hughes' syndrome: the antiphospholipid syndrome. A historical view.  Lupus. 1998;  7(suppl 2) S1-S4
• 30 Harris E N. Syndrome of the black swan.  Br J Rheumatol. 1987;  26 324-326
• 31 Galli M, Comfurius P, Maassen C et al.. Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor.  Lancet. 1990;  335 1544-1547
• 32 McNeil H P, Simpson R J, Chesterman C N, Krilis S A. Anti-phospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: beta 2-glycoprotein I (apolipoprotein H).  Proc Natl Acad Sci USA. 1990;  87 4120-4124
• 33 Roubey R AS. Autoantibodies to phospholipid-binding plasma proteins: A new view of lupus anticoagulants and other “antiphospholipid” antibodies.  Blood. 1994;  84 2854-2867
• 34 Hunt J E, McNeil H P, Morgan G J, Crameri R M, Krilis S A. A phospholipid-beta 2-glycoprotein I complex is an antigen for anticardiolipin antibodies occurring in autoimmune disease but not with infection.  Lupus. 1992;  1 75-81
• 35 Lubbe W F, Butler W S, Palmer S J, Liggins G C. Fetal survival after prednisone suppression of maternal lupus-anticoagulant.  Lancet. 1983;  1 1361-1363
• 36 6th International Symposium on Antiphospholipid Antibodies. Leuven, Belgium, 14-17 September 1994. Proceedings.  Lupus. 1994;  3 207-364
• 37 Oshiro B T, Silver R M, Scott J R, Yu H, Branch D W. Antiphospholipid antibodies and fetal death.  Obstet Gynecol. 1996;  87 489-493
• 38 Lockshin M D, Druzin M, Goei S et al.. Antibody to cardiolipin as a predictor of fetal distress or death in pregnant patients with systemic lupus erythematosus.  N Engl J Med. 1985;  313 152-156
• 39 De Wolf F, Carreras L O, Moerman P, Vermylen J, Van A A, Renaer M. Decidual vasculopathy and extensive placental infarction in a patient with repeated thromboembolic accidents, recurrent fetal loss, and a lupus anticoagulant.  Am J Obstet Gynecol. 1982;  142 829-834
• 40 Levine J S, Branch D W, Rauch J. The antiphospholipid syndrome.  N Engl J Med. 2002;  346 752-763
• 41 Brandt J T, Triplett D A, Alving B, Scharrer I. Criteria for the diagnosis of lupus anticoagulants: an update. On behalf of the Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the ISTH.  Thromb Haemost. 1995;  74 1185-1190
• 42 Favaloro E J, Silvestrini R, Mohammed A. Clinical utility of anticardiolipin antibody assays: High inter-laboratory variation and limited consensus by participants of external quality assurance programs signals a cautious approach.  Pathology. 1999;  31 142-147
• 43 Silver R M, Porter T F, van Leeuween I, Jeng G, Scott J R, Branch D W. Anticardiolipin antibodies: clinical consequences of “low titers”.  Obstet Gynecol. 1996;  87 494-500
• 44 Yetman D L, Kutteh W H. Antiphospholipid antibody panels and recurrent pregnancy loss: prevalence of anticardiolipin antibodies compared with other antiphospholipid antibodies.  Fertil Steril. 1996;  66 540-546
• 45 Aoki K, Hayashi Y, Hirao Y, Yagami Y. Specific antiphospholipid antibodies as a predictive variable in patients with recurrent pregnancy loss.  Am J Reprod Immunol. 1993;  29 82-87
• 46 Carreras L O, Forastiero R R, Marttunen M E. Which are the best biological markers of the antiphospholipid syndrome?.  J Autoimmun. 2000;  15 163-172
• 47 Cabral A R, Amigo M C, Cabiedes J, Alarcon-Segovia D. The antiphospholipid/cofactor syndromes: a primary variant with antibodies to b2-glycoprotein-I but no antibodies detectable in standard antiphospholipid assays.  Am J Med. 1996;  101 472-481
• 48 Lee R M, Emlen W, Scott J R, Branch D W, Silver R M. Anti-beta2-glycoprotein I antibodies in women with recurrent spontaneous abortion, unexplained fetal death, and antiphospholipid syndrome.  Am J Obstet Gynecol. 1999;  181 642-648
• 49 Bertolaccini M L, Roch B, Amengual O, Atsumi T, Khamashta M A, Hughes G R. Multiple antiphospholipid tests do not increase the diagnostic yield in antiphospholipid syndrome.  Br J Rheumatol. 1998;  37 1229-1232
• 50 Adler R R, Ng A K, Rote N S. Monoclonal antiphosphatidylserine antibody inhibits intercellular fusion of the choriocarcinoma line, JAR.  Biol Reprod. 1995;  53 905-910
• 51 Katsuragawa H, Kanzaki H, Inoue T, Hirano T, Mori T, Rote N S. Monoclonal antibody against phosphatidylserine inhibits in vitro human trophoblastic hormone production and invasion.  Biol Reprod. 1997;  56 50-58
• 52 Sebire N J, Backos M, El Gaddal S, Goldin R D, Regan L. Placental pathology, antiphospholipid antibodies, and pregnancy outcome in recurrent miscarriage patients.  Obstet Gynecol. 2003;  101 258-263
• 53 Sebire N J, Fox H, Backos M, Rai R, Paterson C, Regan L. Defective endovascular trophoblast invasion in primary antiphospholipid antibody syndrome-associated early pregnancy failure.  Hum Reprod. 2002;  17 1067-1071
• 54 Burrows T D, King A, Loke Y W. Trophoblast migration during human placental implantation.  Hum Reprod Update. 1996;  2 307-321
• 55 Quenby S, Mountfield S, Cartwright J E, Whitley G S, Chamley L, Vince G. Antiphospholipid antibodies prevent extravillous trophoblast differentiation.  Fertil Steril. 2005;  83 691-698
• 56 Di Simone N, Caliandro D, Castellani R, Ferrazzani S, De Carolis S, Caruso A. Low-molecular weight heparin restores in-vitro trophoblast invasiveness and differentiation in presence of immunoglobulin G fractions obtained from patients with antiphospholipid syndrome.  Hum Reprod. 1999;  14 489-495
• 57 Cariou R, Tobelem G, Soria C, Caen J. Inhibition of protein C activation by endothelial cells in the presence of lupus anticoagulant.  N Engl J Med. 1986;  314 1193-1194
• 58 Cosgriff T M, Martin B A. Low functional and high antigenic antithrombin III level in a patient with the lupus anticoagulant and recurrent thrombosis.  Arthritis Rheum. 1981;  24 94-96
• 59 Peaceman A M, Rehnberg K A. The immunoglobulin G fraction from plasma containing antiphospholipid antibodies causes increased placental thromboxane production.  Am J Obstet Gynecol. 1992;  167 1543-1547
• 60 Rand J H, Wu X X, Andree H A et al.. Pregnancy loss in the antiphospholipid-antibody syndrome-a possible thrombogenic mechanism.  N Engl J Med. 1997;  337 154-160
• 61 Wiener H M, Vardinon N, Yust I. Platelet antibody binding and spontaneous aggregation in 21 lupus anticoagulant patients.  Vox Sang. 1991;  61 111-121
• 62 Lin Y-L, Wang C-T. Activation of human platelets by rabbit anticardiolipin antibodies.  Blood. 1992;  80 3135-3143
• 63 Meroni P L, Raschi E, Camera M et al.. Endothelial activation by aPL: a potential pathogenetic mechanism for the clinical manifestations of the syndrome.  J Autoimmun. 2000;  15 237-240
• 64 Vaarala O, Alfthan G, Jauhiainen M, Leirisalo Repo M, Aho K, Palosuo T. Crossreaction between antibodies to oxidised low-density lipoprotein and to cardiolipin in systemic lupus erythematosus.  Lancet. 1993;  341 923-925
• 65 Witztum J L, Horkko S. The role of oxidized LDL in atherogenesis: immunological response and antiphospholipid antibodies.  Ann NY Acad Sci. 1997;  811 88-96
• 66 Horkko S, Miller E, Dudl E et al.. Antiphospholipid antibodies are directed against epitopes of oxidized phospholipids: recognition of cardiolipin by monoclonal antibodies to epitopes of oxidized low density lipoprotein.  J Clin Invest. 1996;  98 815-825
• 67 Voges D, Berendes R, Burger A, Demange P, Baumeister W, Huber R. Three-dimensional structure of membrane-bound annexin V. A correlative electron microscopy-X-ray crystallography study.  J Mol Biol. 1994;  238 199-213
• 68 Mosser G, Ravanat C, Freyssinet J M, Brisson A. Sub-domain structure of lipid-bound annexin-V resolved by electron image analysis.  J Mol Biol. 1991;  217 241-245
• 69 Andree H A, Hermens W T, Hemker H C. Displacement of factor Va by annexin V. In: Andree HA Phospholipid Binding and Anticoagulant Action of Annexin V. Maastricht, The Netherlands; Universitaire Pers Maastricht 1992: 73-85
• 70 Rand J H, Wu X X, Quinn A S et al.. Human monoclonal antiphospholipid antibodies disrupt the annexin A5 anticoagulant crystal shield on phospholipid bilayers: evidence from atomic force microscopy and functional assay.  Am J Pathol. 2003;  163 1193-1200
• 71 Rand J H. Molecular pathogenesis of the antiphospholipid syndrome.  Circ Res. 2002;  90 29-37
• 72 Krikun G, Lockwood C J, Wu X X et al.. The expression of the placental anticoagulant protein, annexin V, by villous trophoblasts: immunolocalization and in vitro regulation.  Placenta. 1994;  15 601-612
• 73 Lyden T W, Vogt E, Ng A K, Johnson P M, Rote N S. Monoclonal antiphospholipid antibody reactivity against human placental trophoblast.  J Reprod Immunol. 1992;  22 1-14
• 74 Rand J H, Wu X X, Andree H A et al.. Antiphospholipid antibodies accelerate plasma coagulation by inhibiting annexin-V binding to phospholipids: a “lupus procoagulant” phenomenon.  Blood. 1998;  92 1652-1660
• 75 Wang X, Campos B, Kaetzel M A, Dedman J R. Annexin V is critical in the maintenance of murine placental integrity.  Am J Obstet Gynecol. 1999;  180 1008-1016
• 76 Rand J H, Wu X X, Guller S et al.. Reduction of annexin-V (placental anticoagulant protein-I) on placental villi of women with antiphospholipid antibodies and recurrent spontaneous abortion.  Am J Obstet Gynecol. 1994;  171 1566-1572
• 77 Rand J H, Wu X X, Guller S, Scher J, Andree H A, Lockwood C J. Antiphospholipid immunoglobulin G antibodies reduce annexin-V levels on syncytiotrophoblast apical membranes and in culture media of placental villi.  Am J Obstet Gynecol. 1997;  177 918-923
• 78 Vogt E, Ng A K, Rote N S. Antiphosphatidylserine antibody removes annexin-V and facilitates the binding of prothrombin at the surface of a choriocarcinoma model of trophoblast differentiation.  Am J Obstet Gynecol. 1997;  177 964-972
• 79 Miyakis S, Giannakopoulos B, Krilis S A. Beta 2 glycoprotein I-function in health and disease.  Thromb Res. 2004;  114 335-346
• 80 Ieko M, Ichikawa K, Triplett D A et al.. Beta2-glycoprotein I is necessary to inhibit protein C activity by monoclonal anticardiolipin antibodies.  Arthritis Rheum. 1999;  42 167-174
• 81 Schousboe I, Rasmussen M S. Synchronized inhibition of the phospholipid mediated autoactivation of factor XII in plasma by beta 2-glycoprotein I and anti-beta 2-glycoprotein I.  Thromb Haemost. 1995;  73 798-804
• 82 Shi T, Iverson G M, Qi J C et al.. Beta 2-Glycoprotein I binds factor XI and inhibits its activation by thrombin and factor XIIa: loss of inhibition by clipped beta 2-glycoprotein I.  Proc Natl Acad Sci USA. 2004;  101 3939-3944
• 83 Bas de L H, Derksen R H, de Groot P G. beta2-glycoprotein I, the playmaker of the antiphospholipid syndrome.  Clin Immunol. 2004;  112 161-168
• 84 Amengual O, Atsumi T, Khamashta M A, Hughes G R. The role of the tissue factor pathway in the hypercoagulable state in patients with the antiphospholipid syndrome.  Thromb Haemost. 1998;  79 276-281
• 85 Gharavi A E, Pierangeli S S, Colden-Stanfield M, Liu X W, Espinola R G, Harris E N. GDKV-induced antiphospholipid antibodies enhance thrombosis and activate endothelial cells in vivo and in vitro.  J Immunol. 1999;  163 2922-2927
• 86 Rote N S, Vogt E, DeVere G, Obringer A R, Ng A K. The role of placental trophoblast in the pathophysiology of the antiphospholipid antibody syndrome.  Am J Reprod Immunol. 1998;  39 125-136
• 87 Di Simone N, Raschi E, Testoni C et al.. Pathogenic role of anti-{beta}2-glycoprotein I antibodies in antiphospholipid associated fetal loss: characterisation of {beta}2-glycoprotein I binding to trophoblast cells and functional effects of anti-{beta}2-glycoprotein I antibodies in vitro.  Ann Rheum Dis. 2005;  64 462-467
• 88 Sheng Y, Reddel S W, Herzog H et al.. Impaired thrombin generation in beta 2-glycoprotein I null mice.  J Biol Chem. 2001;  276 13817-13821
• 89 Robertson S A, Roberts C T, van Beijering E et al.. Effect of beta2-glycoprotein I null mutation on reproductive outcome and antiphospholipid antibody-mediated pregnancy pathology in mice.  Mol Hum Reprod. 2004;  10 409-416
• 90 Yasuda S, Tsutsumi A, Chiba H et al.. beta(2)-glycoprotein I deficiency: prevalence, genetic background and effects on plasma lipoprotein metabolism and hemostasis.  Atherosclerosis. 2000;  152 337-346
• 91 Blank M, Shoenfeld Y. Beta-2-glycoprotein-I, infections, antiphospholipid syndrome and therapeutic considerations.  Clin Immunol. 2004;  112 190-199
• 92 Girardi G, Salmon J B. The role of complement in pregnancy and fetal loss.  Autoimmunity. 2003;  36 19-26
• 93 Salmon J E, Girardi G. The role of complement in the antiphospholipid syndrome.  Curr Dir Autoimmun. 2004;  7 133-148
• 94 Salmon J E, Girardi G, Holers V M. Activation of complement mediates antiphospholipid antibody-induced pregnancy loss.  Lupus. 2003;  12 535-538
• 95 Di Simone N, Meroni P L, de Papa N et al.. Antiphospholipid antibodies affect trophoblast gonadotropin secretion and invasiveness by binding directly and through adhered beta2-glycoprotein I.  Arthritis Rheum. 2000;  43 140-150
• 96 Pierangeli S S, Colden-Stanfield M, Liu X, Barker J H, Anderson G L, Harris E N. Antiphospholipid antibodies from antiphospholipid syndrome patients activate endothelial cells in vitro and in vivo.  Circulation. 1999;  99 1997-2002
• 97 Tedesco F, Narchi G, Radillo O, Meri S, Ferrone S, Betterle C. Susceptibility of human trophoblast to killing by human complement and the role of the complement regulatory proteins.  J Immunol. 1993;  151 1562-1570
• 98 Holers V M, Girardi G, Mo L et al.. Complement C3 activation is required for antiphospholipid antibody-induced fetal loss.  J Exp Med. 2002;  195 211-220
• 99 Girardi G, Berman J, Redecha P et al.. Complement C5a receptors and neutrophils mediate fetal injury in the antiphospholipid syndrome.  J Clin Invest. 2003;  112 1644-1654
• 100 Cowchock F S, Reece E A, Balaban D, Branch D W, Plouffe L. Repeated fetal losses associated with antiphospholipid antibodies: a collaborative randomized trial comparing prednisone with low-dose heparin treatment.  Am J Obstet Gynecol. 1992;  166 1318-1323
• 101 Stephenson M D, Ballem P J, Tsang P et al.. Treatment of antiphospholipid antibody syndrome (APS) in pregnancy: a randomized pilot trial comparing low molecular weight heparin to unfractionated heparin.  J Obstet Gynaecol Can. 2004;  26 729-734
• 102 Noble L S, Kutteh W H, Lashey N, Franklin R D, Herrada J. Antiphospholipid antibodies associated with recurrent pregnancy loss: prospective, multicenter, controlled pilot study comparing treatment with low-molecular-weight heparin versus unfractionated heparin.  Fertil Steril. 2005;  83 684-690
• 103 Bose P, Black S, Kadyrov M et al.. Heparin and aspirin attenuate placental apoptosis in vitro: implications for early pregnancy failure.  Am J Obstet Gynecol. 2005;  192 23-30
• 104 Di Simone N, Ferrazzani S, Castellani R, De Carolis S, Mancuso S, Caruso A. Heparin and low-dose aspirin restore placental human chorionic gonadotrophin secretion abolished by antiphospholipid antibody-containing sera.  Hum Reprod. 1997;  12 2061-2065
• 105 Franklin R D, Kutteh W H. Effects of unfractionated and low molecular weight heparin on antiphospholipid antibody binding in vitro.  Obstet Gynecol. 2003;  101 455-462
• 106 Girardi G, Redecha P, Salmon J E. Heparin prevents antiphospholipid antibody-induced fetal loss by inhibiting complement activation.  Nat Med. 2004;  10 1222-1226
• 107 Spinnato J A, Clark A L, Pierangeli S S, Harris E N. Intravenous immunoglobulin therapy for the antiphospholipid syndrome in pregnancy.  Am J Obstet Gynecol. 1995;  172 690-694
• 108 Pattison N S, Chamley L W, Birdsall M, Zanderigo A M, Liddell H S, McDougall J. Does aspirin have a role in improving pregnancy outcome for women with the antiphospholipid syndrome? A randomized controlled trial.  Am J Obstet Gynecol. 2000;  183 1008-1012
• 109 Cowchock S, Reece E A. Do low-risk pregnant women with antiphospholipid antibodies need to be treated?.  Am J Obstet Gynecol. 1997;  176 1099-1100
• 110 Tulppala M, Marttunen M, Soderstrom-Anttila V et al.. Low-dose aspirin in prevention of miscarriage in women with unexplained or autoimmune related recurrent miscarriage: effect on prostacyclin and thromboxane A2 production.  Hum Reprod. 1997;  12 1567-1572
• 111 Kutteh W H. Antiphospholipid antibody-associated recurrent pregnancy loss: treatment with heparin and low-dose aspirin is superior to low-dose aspirin alone.  Am J Obstet Gynecol. 1996;  174 1584-1589
• 112 Rai R, Cohen H, Dave M, Regan L. Randomised controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with phospholipid antibodies (or antiphospholipid antibodies).  BMJ. 1997;  314 253-257
• 113 Silver R K, MacGregor S N, Sholl J S, Hobart J M, Neerhof M G, Ragin A. Comparative trial of prednisone plus aspirin versus aspirin alone in the treatment of anticardiolipin antibody-positive obstetric patients.  Am J Obstet Gynecol. 1993;  169 1411-1417
• 114 Laskin C A, Bombardier C, Hannah M E et al.. Prednisone and aspirin in women with autoantibodies and unexplained recurrent fetal loss.  N Engl J Med. 1997;  337 148-153
• 115 Gardlund B. The lupus inhibitors in thromboembolic disease and intrasuterine fetal death in the absence of systemic lupus.  Acta Med Scand. 1984;  5 293-298
• 116 Kandrotas R J. Heparin pharmacokinetics and pharmacodynamics.  Clin Pharmacokinet. 1992;  22 359-374
• 117 Kutteh W H, Ermel L D. A clinical trial for the treatment of antiphospholipid antibody-associated recurrent pregnancy loss with lower dose heparin and aspirin.  Am J Reprod Immunol. 1996;  35 402-407
• 118 Farquharson R G, Quenby S, Greaves M. Antiphospholipid syndrome in pregnancy: a randomized, controlled trial of treatment.  Obstet Gynecol. 2002;  100 408-413
• 119 Branch D W, Peaceman A M, Druzin M et al.. A multicenter, placebo-controlled pilot study of intravenous immune globulin treatment of antiphospholipid syndrome during pregnancy. The Pregnancy Loss Study Group.  Am J Obstet Gynecol. 2000;  182 122-127
• 120 Ensom M HH, Stephenson M D. Low-molecular-weight heparins in pregnancy.  Pharmacotherapy. 1999;  19 1013-1025
• 121 Triolo G, Ferrante A, Ciccia F et al.. Randomized study of subcutaneous low molecular weight heparin plus aspirin versus intravenous immunoglobulin in the treatment of recurrent fetal loss associated with antiphospholipid antibodies.  Arthritis Rheum. 2003;  48 728-731
• 122 Clark A L, Branch D W, Silver R M, Harris E N, Pierangeli S, Spinnato J A. Pregnancy complicated by the antiphospholipid syndrome: outcomes with intravenous immunoglobulin therapy.  Obstet Gynecol. 1999;  93 437-441
• 123 Stephenson M D, Houlihan E, Tsang P, Ensworth S, Lim K, Ballem P J. Concomitant use of IVIG for treatment of the antiphospholipid antibody syndrome (APS) when ASA and heparin results in at least one adverse pregnancy outcome.  Lupus. 2002;  11 694
• 124 Lynch A, Marlar R, Murphy J et al.. Antiphospholipid antibodies in predicting adverse pregnancy outcome.  Ann Intern Med. 1994;  120 470-475
• 125 Yasuda M, Takakuwa K, Tokunaga A, Tanaka K. Prospective studies of the association between anticardiolipin antibody and outcome of pregnancy.  Obstet Gynecol. 1995;  86 555-559
• 126 Petri M. Epidemiology of the antiphospholipid antibody syndrome.  J Autoimmun. 2000;  15 145-151
• 127 Lockshin M D, Druzin M L, Qamar T. Prednisone does not prevent recurrent fetal death in women with antiphospholipid antibody.  Am J Obstet Gynecol. 1989;  160 439-443
• 128 Bahar A M, Kwak J Y, Beer A E et al.. Antibodies to phospholipids and nuclear antigens in non-pregnant women with unexplained spontaneous recurrent abortions.  J Reprod Immunol. 1993;  24 213-222
• 129 Ruiz J E, Cubillos J, Mendoza J C, Espinel F J, Kwak J Y, Beer A E. Autoantibodies to phospholipids and nuclear antigens in non-pregnant and pregnant Columbian women with recurrent spontaneous abortions.  J Reprod Immunol. 1995;  28 41-51
• 130 Kutteh W H, Franklin R D. Assessing the variation in antiphospholipid antibody (APA) assays: comparison of results from 10 centers.  Am J Obstet Gynecol. 2004;  191 440-448